Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01841723 · ClinicalTrials.gov registry record · Phase 2
Ibrutinib in Treating Patients With Relapsed Hairy Cell Leukemia
A Phase 2 study of Hairy Cell Leukemia and Recurrent Hairy Cell Leukemia, sponsored by National Cancer Institute (NCI).
- Active
- Registry status
- Phase 2
- Development phase
- 44
- Enrollment target
- 5
- Study locations
NCT01841723 is a Phase 2 study of Hairy Cell Leukemia and Recurrent Hairy Cell Leukemia that is active but no longer recruiting, run by National Cancer Institute (NCI). The registered enrollment target is 44 participants, below the 70-participant average among 15 other Hairy Cell Leukemia trials with a reported enrollment target (37% lower). The trial reports 5 study locations across 5 states.
The verdict
NCT01841723, a Phase 2 study of Hairy Cell Leukemia and Recurrent Hairy Cell Leukemia, is active but no longer recruiting, sponsored by National Cancer Institute (NCI).
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 44 participants
- Enrollment target
- 5
- Study locations
Study Summary
This phase II trial studies how well ibrutinib works in treating patients with hairy cell leukemia that has returned after a period of improvement. Ibrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
Conditions Studied
Interventions
- PROCEDURE Biospecimen Collection
- PROCEDURE Bone Marrow Aspiration
- PROCEDURE Bone Marrow Biopsy
- PROCEDURE Computed Tomography
- DRUG Ibrutinib
Study Locations (5)
Maryland
- National Institutes of Health Clinical Center - Bethesda
Michigan
- Wayne State University/Karmanos Cancer Institute - Detroit
Minnesota
- Mayo Clinic in Rochester - Rochester
Ohio
- Ohio State University Comprehensive Cancer Center - Columbus
Texas
- M D Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 44 participants |
| Start Date | 2013-04-30 |
| Est. Completion | 2029-12-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01841723
The ClinicalTrials.gov registry entry for NCT01841723 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 44 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 70-participant average among 15 other Hairy Cell Leukemia trials with a reported enrollment target (37% lower). The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Hairy Cell Leukemia appearing as the primary indexed condition, and to 5 interventions - of which Biospecimen Collection is the first listed.
NCT01841723 reports 5 study locations spanning 5 distinct geographic areas - top geographies include Maryland, Michigan, Minnesota.
Frequently Asked Questions
What is clinical trial NCT01841723 about?
NCT01841723 is a clinical study titled "Ibrutinib in Treating Patients With Relapsed Hairy Cell Leukemia". This phase II trial studies how well ibrutinib works in treating patients with hairy cell leukemia that has returned after a period of improvement. Ibrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
What is the current status of trial NCT01841723?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 44 participants. The study started on 2013-04-30. Estimated completion is 2029-12-31.
What conditions does trial NCT01841723 study?
This clinical trial studies the following conditions: Hairy Cell Leukemia, Recurrent Hairy Cell Leukemia, Recurrent Hairy Cell Leukemia Variant, Hairy Cell Leukemia Variant.
What interventions are being tested in trial NCT01841723?
The interventions under investigation include: Biospecimen Collection (PROCEDURE), Bone Marrow Aspiration (PROCEDURE), Bone Marrow Biopsy (PROCEDURE), Computed Tomography (PROCEDURE), Ibrutinib (DRUG).
Who is sponsoring clinical trial NCT01841723?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01841723 being conducted?
This trial has 5 study locations across Maryland, Michigan, Minnesota, Ohio, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hairy Cell Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Vemurafenib and Obinutuzumab Compared to Cladribine and Rituximab in People With Hairy Cell Leukemia (HCL)
RECRUITING · Phase 2
-
Binimetinib for People With Relapsed/Refractory BRAF Wild Type Hairy Cell Leukemia and Variant
RECRUITING · Phase 2
-
Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia
RECRUITING · Phase 2
-
Encorafenib Plus Binimetinib for People With BRAF V600 Mutated Relapsed/Refractory HCL
RECRUITING · Phase 2
-
Cladribine With Simultaneous or Delayed Rituximab to Treat Hairy Cell Leukemia
ACTIVE NOT RECRUITING · Phase 2
-
A Phase II Study of the BRAF Inhibitor, Vemurafenib, Plus Obinutuzumab in Patients With Previously Untreated Classical Hairy Cell Leukemia
ACTIVE NOT RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.